The global scar treatment market size was USD 26.50 billion in 2023, estimated at USD 29.25 billion in 2024 and is anticipated to reach around USD 76.20 billion by 2034, expanding at a CAGR of 10.05% from 2024 to 2034.
The global scar treatment market size accounted for USD 29.25 billion in 2024 and is predicted to reach around USD 76.20 billion by 2034, growing at a CAGR of 10.05% from 2024 to 2034.
Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare
The U.S. scar treatment market size was valued at USD 7.05 billion in 2023 and is estimated to reach around USD 20.44 billion by 2034, growing at a CAGR of 10.13% from 2024 to 2034.
The North America accounted the market with 38% revenue share in 2023 and is estimated to sustain its dominance during the forecast period. This is attributable to the higher awareness among the population regarding their aesthetic appearance, easy availability of scar treatment products, increased personal disposable income, developed infrastructure in hospitals, and higher adoption of technologically advanced equipment. Moreover, rising cases of burn injuries is fostering the market in North America. As per the American Burn Association, there are more than 485,000 burn injury cases reported in US every year. Further, the presence of some of the key market players in US such as CCA Industries, Scar Heal, Inc., and Sonoma Pharmaceuticals are contributing significantly in the growth of the scar treatment market in this region.
Asia Pacific region is estimated the highest CAGR of 12% during the forecast period. This is majorly due to the growing infrastructural investments by the government and private players in the healthcare and pharmaceutical industry, growing number of road accident cases, and rising awareness among the population regarding aesthetic appearances. According to the WHO, around 93% of the global road accidents occur in underdeveloped and developing countries. Moreover, developing nation like India is a leading contributor to the global road accident cases. Hence, the growing number of road accidents is a major contributing factor to the growth of the scar treatment market in the region.
The growing concerns among the population regarding their aesthetic appearances are a major factor driving the growth of the global scar treatment market. Scars due to accidents and other reasons is propelling the demand for the scar treatment products and services. The growing demand among women for improving aesthetic appeal and skin rejuvenation is significantly driving the market growth. Moreover, rising prevalence of skin diseases and increasing awareness regarding scar treatment among the population is fueling the market growth globally. The excessive exposure to sunlight and pollution may cause skin disease such as photo-aging, psoriasis, sunburns, and vitiligo. These diseases may lead to scars if not treated properly. Other scars such as burns, acne, stretch marks, and surgical scars are the various factors that are exponentially contributing towards the skin treatment market growth globally.
The growth in the number of road accidents across the globe is another driving factor for the scar treatment market. According to a data published by the Population Reference Bureau, every year, around 50 million individuals are injured due to road accidents. According to the World Health Organization, around 1.3 million people die in road accidents every year. Moreover, the children and the young adults are the major victims of road accidents. Hence, these two age groups are one of the consumers of scar treatment products. Hence, the rising number of road accident cases is fueling the growth of the global scar treatment market.
Report Coverage | Details |
Market Size in 2023 | USD 26.50 Billion |
Market Size in 2024 | USD 29.25 Billion |
Market Size by 2034 | USD 76.20 Billion |
Growth Rate from 2024 to 2034 | CAGR of 10.05% |
Base Year | 2023 |
Forecast Period | 2024 to 2034 |
Largest Market | North America |
Segments Covered | Treatment Type, Scar Type, End Use, Region |
Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
The topical segment led the largest revenue share 60.5% in 2023 and is anticipated to retain its dominance throughout the forecast period. This is attributed to the growing demand and easy availability of the topical products such as silicone sheets, gels, oils, ointments, sprays, and creams. These products are directly applied on the skin by the consumers to treat scars. These are easily available over the counter products. Moreover, the rising penetration of retail pharmacies and online pharmacies are expected to fuel the growth of the segment.
On the other hand, the laser is estimated to be the most opportunistic segment during the forecast period. Laser scar treatment is the latest and advanced technology for scar treatment. Moreover, laser treatment of scars is painless and non-invasive and it provides instant results without any discomfort. Hence, this is expected to be the fastest-growing segment in the forthcoming years.
The acne & atrophic segment led the global scar treatment market with remarkable revenue share in 2023 and is anticipated to retain its dominance throughout the forecast period. Acne & atrophic scars occurs due to the insufficiency of skin to produce adequate collagen to heal the scare or injury. These types of scars are generally treated with lotions, oils, gels, and creams that are easily available as OTC products.
On the other hand, the hypertrophic & keloid is anticipated to be the most opportunistic segment during the forecast period. This is attributed to the rising number of traumatic wounds, surgical procedures, and burn injuries. Moreover, growing cases of road accidents is fueling the growth of this segment.
The home-use segment accounted the market with revenue share of 45% in 2023 and is anticipated to retain its dominance throughout the forecast period. This is attributable to the growing consumption of topical products such as silicone sheets, creams, and lotions by the consumers to treat scars.
On the other hand, the hospitals are expected to be the fastest-growing segment during the forecast period, due to the availability of advanced technologies and cosmopolitan infrastructure for scar treatment.
The market is moderately fragmented with the presence of several local companies. These market players are striving to gain higher market share by adopting strategies, such as investments, partnerships, and acquisitions & mergers. Companies are also spending on the development of improved and efficient products. Moreover, they are also focusing on maintaining competitive pricing.
In June 2020, Bausch Health launched ARAZLO lotion in US that is useful in the treatment of scars such as acne, whiteheads, and blackheads removal.
In January 2019, AVITA Medical launched Autologous Cell Harvesting Device for the treatment of burns.
These developmental strategies significantly contribute to the growth of the scar treatment market.
Segments Covered in the Report
By Treatment Type
By Scar Type
By End Use
By Geography
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Scar Treatment Market, By Treatment
7.1. Scar Treatment Market, by Treatment Type, 2024-2034
7.1.1. Topical
7.1.1.1. Market Revenue and Forecast (2021-2034)
7.1.2. Laser
7.1.2.1. Market Revenue and Forecast (2021-2034)
7.1.3. Surface
7.1.3.1. Market Revenue and Forecast (2021-2034)
7.1.4. Surgical
7.1.4.1. Market Revenue and Forecast (2021-2034)
7.1.5. Injectable
7.1.5.1. Market Revenue and Forecast (2021-2034)
Chapter 8. Global Scar Treatment Market, By End Use
8.1. Scar Treatment Market, by End Use, 2024-2034
8.1.1. Dermatology Clinics
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Home-Use
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Hospitals
8.1.3.1. Market Revenue and Forecast (2021-2034)
Chapter 9. Global Scar Treatment Market, By Scar
9.1. Scar Treatment Market, by Scar, 2024-2034
9.1.1. Acne & Atrophic
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Stretch Marks
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Hypertrophic & Keloid
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Contracture
9.1.4.1. Market Revenue and Forecast (2021-2034)
Chapter 10. Global Scar Treatment Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.1.2. Market Revenue and Forecast, by End Use (2021-2034)
10.1.3. Market Revenue and Forecast, by Scar (2021-2034)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.1.4.2. Market Revenue and Forecast, by End Use (2021-2034)
10.1.4.3. Market Revenue and Forecast, by Scar (2021-2034)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.1.5.2. Market Revenue and Forecast, by End Use (2021-2034)
10.1.5.3. Market Revenue and Forecast, by Scar (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.2.2. Market Revenue and Forecast, by End Use (2021-2034)
10.2.3. Market Revenue and Forecast, by Scar (2021-2034)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.2.4.2. Market Revenue and Forecast, by End Use (2021-2034)
10.2.4.3. Market Revenue and Forecast, by Scar (2021-2034)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.2.5.2. Market Revenue and Forecast, by End Use (2021-2034)
10.2.5.3. Market Revenue and Forecast, by Scar (2021-2034)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.2.6.2. Market Revenue and Forecast, by End Use (2021-2034)
10.2.6.3. Market Revenue and Forecast, by Scar (2021-2034)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.2.7.2. Market Revenue and Forecast, by End Use (2021-2034)
10.2.7.3. Market Revenue and Forecast, by Scar (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.3.2. Market Revenue and Forecast, by End Use (2021-2034)
10.3.3. Market Revenue and Forecast, by Scar (2021-2034)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.3.4.2. Market Revenue and Forecast, by End Use (2021-2034)
10.3.4.3. Market Revenue and Forecast, by Scar (2021-2034)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.3.5.2. Market Revenue and Forecast, by End Use (2021-2034)
10.3.5.3. Market Revenue and Forecast, by Scar (2021-2034)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.3.6.2. Market Revenue and Forecast, by End Use (2021-2034)
10.3.6.3. Market Revenue and Forecast, by Scar (2021-2034)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.3.7.2. Market Revenue and Forecast, by End Use (2021-2034)
10.3.7.3. Market Revenue and Forecast, by Scar (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.4.2. Market Revenue and Forecast, by End Use (2021-2034)
10.4.3. Market Revenue and Forecast, by Scar (2021-2034)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.4.4.2. Market Revenue and Forecast, by End Use (2021-2034)
10.4.4.3. Market Revenue and Forecast, by Scar (2021-2034)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.4.5.2. Market Revenue and Forecast, by End Use (2021-2034)
10.4.5.3. Market Revenue and Forecast, by Scar (2021-2034)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.4.6.2. Market Revenue and Forecast, by End Use (2021-2034)
10.4.6.3. Market Revenue and Forecast, by Scar (2021-2034)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.4.7.2. Market Revenue and Forecast, by End Use (2021-2034)
10.4.7.3. Market Revenue and Forecast, by Scar (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.5.2. Market Revenue and Forecast, by End Use (2021-2034)
10.5.3. Market Revenue and Forecast, by Scar (2021-2034)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.5.4.2. Market Revenue and Forecast, by End Use (2021-2034)
10.5.4.3. Market Revenue and Forecast, by Scar (2021-2034)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, by Treatment (2021-2034)
10.5.5.2. Market Revenue and Forecast, by End Use (2021-2034)
10.5.5.3. Market Revenue and Forecast, by Scar (2021-2034)
Chapter 11. Company Profiles
11.1. Bausch Health Companies, Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Candela Corp.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Sonoma Pharmaceuticals, Inc.
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Hologic, Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Johnson & Johnson
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Quantum, Inc.
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. CCA Industries, Inc.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Avita Medical Ltd.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Revitol Corp.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Scarguard Labs, LLC.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client